Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study ; volume:44 ; number:03 ; year:2023 ; pages:345-352
Indian journal of medical & paediatric oncology ; 44, Heft 03 (2023), 345-352
- Contributor
-
Ayesha, Sobiya Mahnaz
Hui, Monalisa
Uppin, Shantveer G.
Uppin, Megha Shantveer
Jena, Shubhranshu
Patil, Rajsekhar Shanthappa
Ratnagiri, Ranganath
Paul, Tara Roshni
- DOI
-
10.1055/s-0043-1761412
- URN
-
urn:nbn:de:101:1-2023062911444023330624
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ayesha, Sobiya Mahnaz
- Hui, Monalisa
- Uppin, Shantveer G.
- Uppin, Megha Shantveer
- Jena, Shubhranshu
- Patil, Rajsekhar Shanthappa
- Ratnagiri, Ranganath
- Paul, Tara Roshni
Other Objects (12)
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population